142 related articles for article (PubMed ID: 16732100)
1. Blockade of the complement C5a receptor reduces incisional allodynia, edema, and cytokine expression.
Clark JD; Qiao Y; Li X; Shi X; Angst MS; Yeomans DC
Anesthesiology; 2006 Jun; 104(6):1274-82. PubMed ID: 16732100
[TBL] [Abstract][Full Text] [Related]
2. Increased local concentration of complement C5a contributes to incisional pain in mice.
Jang JH; Liang D; Kido K; Sun Y; Clark DJ; Brennan TJ
J Neuroinflammation; 2011 Jul; 8():80. PubMed ID: 21736743
[TBL] [Abstract][Full Text] [Related]
3. The complement component C5a receptor mediates pain and inflammation in a postsurgical pain model.
Liang DY; Li X; Shi X; Sun Y; Sahbaie P; Li WW; Clark DJ
Pain; 2012 Feb; 153(2):366-372. PubMed ID: 22137294
[TBL] [Abstract][Full Text] [Related]
4. Roles of Gr-1+ leukocytes in postincisional nociceptive sensitization and inflammation.
Sahbaie P; Li X; Shi X; Clark JD
Anesthesiology; 2012 Sep; 117(3):602-12. PubMed ID: 22820848
[TBL] [Abstract][Full Text] [Related]
5. Role of complement C5a in mechanical inflammatory hypernociception: potential use of C5a receptor antagonists to control inflammatory pain.
Ting E; Guerrero AT; Cunha TM; Verri WA; Taylor SM; Woodruff TM; Cunha FQ; Ferreira SH
Br J Pharmacol; 2008 Mar; 153(5):1043-53. PubMed ID: 18084313
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist.
Strachan AJ; Shiels IA; Reid RC; Fairlie DP; Taylor SM
Br J Pharmacol; 2001 Dec; 134(8):1778-86. PubMed ID: 11739255
[TBL] [Abstract][Full Text] [Related]
7. Morphine reduces local cytokine expression and neutrophil infiltration after incision.
Clark JD; Shi X; Li X; Qiao Y; Liang D; Angst MS; Yeomans DC
Mol Pain; 2007 Oct; 3():28. PubMed ID: 17908329
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of C5a-induced neutrophil chemotaxis and macrophage cytokine production in vitro by a new C5a receptor antagonist.
Haynes DR; Harkin DG; Bignold LP; Hutchens MJ; Taylor SM; Fairlie DP
Biochem Pharmacol; 2000 Sep; 60(5):729-33. PubMed ID: 10927032
[TBL] [Abstract][Full Text] [Related]
9. Chronic morphine administration enhances nociceptive sensitivity and local cytokine production after incision.
Liang D; Shi X; Qiao Y; Angst MS; Yeomans DC; Clark JD
Mol Pain; 2008 Feb; 4():7. PubMed ID: 18294378
[TBL] [Abstract][Full Text] [Related]
10. Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat.
Woodruff TM; Strachan AJ; Dryburgh N; Shiels IA; Reid RC; Fairlie DP; Taylor SM
Arthritis Rheum; 2002 Sep; 46(9):2476-85. PubMed ID: 12355496
[TBL] [Abstract][Full Text] [Related]
11. Treatment with anti-C5aR mAb leads to early-onset clinical and mechanistic effects in the murine delayed-type hypersensitivity arthritis model.
Atkinson SM; Nansen A; Usher PA; Sondergaard BC; Mackay CR; Friedrichsen B; Chang CC; Tang R; Skov S; Haase C; Hornum L
Autoimmunity; 2015; 48(7):460-70. PubMed ID: 25915570
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effects of argatroban and C5a receptor antagonist (PMX53) following intracerebral haemorrhage.
Li G; Fan RM; Chen JL; Wang CM; Zeng YC; Han C; Jiao S; Xia XP; Chen W; Yao ST
Clin Exp Immunol; 2014 Feb; 175(2):285-95. PubMed ID: 24117111
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of complement component C5a accelerates the development of atherosclerosis in ApoE-knockout mice.
An G; Li B; Liu X; Zhang M; Gao F; Zhao Y; An F; Zhang Y; Zhang C
Oncotarget; 2016 Aug; 7(35):56060-56070. PubMed ID: 27517153
[TBL] [Abstract][Full Text] [Related]
14. Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease.
Woodruff TM; Pollitt S; Proctor LM; Stocks SZ; Manthey HD; Williams HM; Mahadevan IB; Shiels IA; Taylor SM
J Pharmacol Exp Ther; 2005 Aug; 314(2):811-7. PubMed ID: 15879003
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats.
Arumugam TV; Woodruff TM; Stocks SZ; Proctor LM; Pollitt S; Shiels IA; Reid RC; Fairlie DP; Taylor SM
J Hepatol; 2004 Jun; 40(6):934-41. PubMed ID: 15158333
[TBL] [Abstract][Full Text] [Related]
16. C5a complement and cytokine signaling mediate the pronociceptive effects of complex regional pain syndrome patient IgM in fracture mice.
Shi X; Guo TZ; Li WW; Birklein F; Escolano FL; Herrnberger M; Clark JD; Kingery WS
Pain; 2021 May; 162(5):1400-1415. PubMed ID: 33259455
[TBL] [Abstract][Full Text] [Related]
17. Complement factor C5a as mast cell activator mediates vascular remodelling in vein graft disease.
de Vries MR; Wezel A; Schepers A; van Santbrink PJ; Woodruff TM; Niessen HW; Hamming JF; Kuiper J; Bot I; Quax PH
Cardiovasc Res; 2013 Feb; 97(2):311-20. PubMed ID: 23071133
[TBL] [Abstract][Full Text] [Related]
18. [Effect of complement C5a on the expression of MCP-1 and NGAL in immune kidney injury of trichloroethylene sensitized mice].
Huang LP; Wang F; Dai YY; Xu QY; Zhang JX; Zhu QX
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2020 Mar; 38(3):161-167. PubMed ID: 32306687
[No Abstract] [Full Text] [Related]
19. Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine.
Arumugam TV; Shiels IA; Woodruff TM; Reid RC; Fairlie DP; Taylor SM
J Surg Res; 2002 Apr; 103(2):260-7. PubMed ID: 11922743
[TBL] [Abstract][Full Text] [Related]
20. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a.
Finch AM; Wong AK; Paczkowski NJ; Wadi SK; Craik DJ; Fairlie DP; Taylor SM
J Med Chem; 1999 Jun; 42(11):1965-74. PubMed ID: 10354404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
